MedPath

A Clinical study to evaluate the efficacy of Ayurvedic rectal suppository in the treatment of Anal Fissure.

Phase 2
Conditions
Health Condition 1: K600- Acute anal fissure
Registration Number
CTRI/2023/10/058232
Lead Sponsor
Dr SHATTARKA G MAHADIK
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients presenting with anal pain and two or more other complaints like bleeding per rectum, painful defecation, constipation and pruritis for a duration of = 6 months.

2.Patients clinically diagnosed of having Acute and Chronic Anal Fissure for a duration of = 6 months presenting with anal pain and two or more other complaints like bleeding per rectum, painful defecation, constipation and pruritis.

3.Patients of either sex will be included.

4.Age 18-60 years old patients included.

5.Patients ready to give informed written consent.

6.Patients ready to abide by the trail procedures meant for this study.

Exclusion Criteria

1.Known cases or suspected cases Irritable Bowel Diseases- Ulcerative diseases and Chron’s diseases.

2.Patients below 18 years and above 60 years of age.

3.Patients with known cases of other Anal conditions like Inflamed or infected Sentinel pile (External tag), Hemorrhoids, Fistula in Ano, Abscess, Proctitis, Malignancy, etc.

4. Patients with following medical conditions requiring stringent medications like

o Hematological conditions- Anemia, thrombocytopenia and bleeding disorders. Poorly controlled hypertension ( >160/100 mm Hg)

o Uncontrolled diabetes mellitus having hemoglobin A1c (HbA1c) > 8%

o With concurrent serious hepatic disorders (defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2 times upper normal limit)

o With Renal disorders (defined as serum creatinine > 1.2 mg/dL),

o With severe pulmonary dysfunction (uncontrolled bronchial asthma and/or chronic obstructive pulmonary disease (COPD))

o Acute and generalized spreading infections

o With Immunocompromised status.

5. Patients on medication with corticosteroids, phototherapy, radiotherapy, chemotherapy, biologics, antidepressants, and any other drugs that may have an influence on the outcome of the study.

6. Pregnant females.

7.History of hypersensitivity to any of the trial drugs or their ingredients.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To study the Shoolghna ( Analgesic) effect of Durvadi Tailam suppository on Anal pain in Anal Fissure in comparison to Diclofenac Suppository.Timepoint: Duration of treatment 7 days. <br/ ><br>Follow up on 3rd 5th 7th 15th day
Secondary Outcome Measures
NameTimeMethod
To assess the Raktasthambak (Haemostatic) effect of the Durvadi Tailam Suppository in Per <br/ ><br>Rectal Bleeding in Parikartika with special reference Anal Fissure. <br/ ><br>2.To assess the Vranaropak (Wound healing) effect of the Durvadi Tailam Suppository in <br/ ><br>Parikartika with special reference Anal Fissure.Timepoint: Duration of treatment 7 days. <br/ ><br>Follow up on 3rd 5th 7th 15th day
© Copyright 2025. All Rights Reserved by MedPath